Discover and read the best of Twitter Threads about #cancerdiagnostics
Most recents (2)
There have been some acquisitions in #CancerDiagnostics and #CancerScreening recently, some of which signify a trend towards consolidation that is worth describing:
$A Agilent is moving towards some more vertical integration in Cancer Dx and Cancer screening
$A Agilent is moving towards some more vertical integration in Cancer Dx and Cancer screening
by recently acquiring both announcing a partnership with Akoya Bio and announcing the acquisition of Avida Biomed. 
Some may ask: isn’t $A Agilent too small to go into this field? Would they be able to compete against $ILMN Illumina/GrailBio or $GH Guardant Health or $EXAS Exact Sciences?
#JPM2021 @carisls My Highlights: in the #CancerDiagnostics area, they position themselves favorably wrt Foundation medicine, Tempus, and Personalis (haven't heard of NEO before).
They put #LiquidBiopsy at the end of this trajectory slide: (couldn't see any years in milestones for this)
No indication that #Caris are pursuing #Epigenomics profiling of #LiquidBiopsy: they mention exome and transcriptome in their slides.
